According to Zacks, analysts expect that Pacira Pharmaceuticals will report full year earnings of ($0.85) per share for the current fiscal year, with EPS estimates ranging from ($1.57) to ($0.52). For the next fiscal year, analysts anticipate that the company will report earnings of $0.27 per share, with EPS estimates ranging from ($1.09) to $1.64. Zacks’ EPS averages are an average based on a survey of analysts that follow Pacira Pharmaceuticals.
Analysts forecast that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) will report earnings of ($0.27) per share for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Pacira Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.47). Pacira Pharmaceuticals reported earnings of ($0.02) per share in the same quarter last year, which would indicate a negative year over year growth rate of 1,250%. The firm is expected to issue its next earnings results on Thursday, August 3rd.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, May 4th. The company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.04. The business had revenue of $69.30 million during the quarter, compared to analyst estimates of $70.30 million. Pacira Pharmaceuticals had a negative net margin of 19.26% and a negative return on equity of 7.71%. Pacira Pharmaceuticals’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.15 EPS.
PCRX has been the subject of a number of research reports. Canaccord Genuity reiterated a “buy” rating and issued a $60.00 price objective on shares of Pacira Pharmaceuticals in a report on Monday, May 15th. HC Wainwright set a $59.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, May 6th. Mizuho reduced their price target on Pacira Pharmaceuticals from $57.00 to $54.00 and set a “buy” rating for the company in a report on Friday, May 5th. Jefferies Group LLC set a $60.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, April 4th. Finally, Royal Bank Of Canada set a $58.00 price target on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $55.25.
In related news, CAO Kristen Marie Williams sold 21,041 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $50.86, for a total value of $1,070,145.26. Following the completion of the sale, the chief accounting officer now directly owns 18,775 shares in the company, valued at approximately $954,896.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Scott Braunstein sold 768 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $43.32, for a total value of $33,269.76. Following the completion of the sale, the senior vice president now owns 9,982 shares of the company’s stock, valued at $432,420.24. The disclosure for this sale can be found here. Insiders sold a total of 50,564 shares of company stock valued at $2,506,682 over the last quarter. 6.60% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. purchased a new position in shares of Pacira Pharmaceuticals during the fourth quarter valued at about $256,000. Renaissance Technologies LLC boosted its position in shares of Pacira Pharmaceuticals by 1.6% in the fourth quarter. Renaissance Technologies LLC now owns 25,200 shares of the company’s stock valued at $814,000 after buying an additional 400 shares during the last quarter. Numeric Investors LLC purchased a new position in shares of Pacira Pharmaceuticals during the fourth quarter valued at about $239,000. Putnam Investments LLC boosted its position in shares of Pacira Pharmaceuticals by 18.6% in the fourth quarter. Putnam Investments LLC now owns 34,549 shares of the company’s stock valued at $1,116,000 after buying an additional 5,410 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Pacira Pharmaceuticals during the fourth quarter valued at about $13,258,000.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded down 1.40% during mid-day trading on Monday, reaching $49.30. 328,687 shares of the company’s stock were exchanged. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95. The stock has a 50-day moving average of $46.14 and a 200 day moving average of $43.48. The firm’s market capitalization is $1.98 billion.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com